Final answer:
Medications that should be monitored for hyperkalemia risk include combinations of ACE inhibitors or ARBs with potassium-sparing diuretics, specifically Lisinopril and Spironolactone as well as Losartan and Spironolactone.
Step-by-step explanation:
The combination of medications that should be monitored carefully due to their increased risk of hyperkalemia is: a. Lisinopril and Spironolactone (Aldactone) and c. Losartan and Spironolactone (Aldactone). Lisinopril is part of a class of medications known as ACE inhibitors, while Losartan belongs to the Angiotensin II Receptor Blockers (or ARBs). Both of these drug types can increase potassium levels in the bloodstream. Spironolactone is a potassium-sparing diuretic, which means it helps the body get rid of excess fluid without causing potassium loss. When either Lisinopril or Losartan is used in conjunction with Spironolactone, the likelihood of retaining too much potassium (hyperkalemia) is enhanced, which necessitates careful monitoring.